LSX Leaders is an influential community of senior life science executives. We produce high quality executive insight and world class deal making, networking and learning opportunities through our exclusive forums and conferences.
Mereo BioPharma Group plc
Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas. Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from AstraZeneca, for the treatment of diseases with considerable unmet medical need.
Therakind is a specialty pharmaceutical company focused on developing medicines in difficult-to-treat markets including paediatric and geriatric patient groups. Out-licensing Jylamvo® oral liquid methotrexate & DriDose® novel nasal powder delivery device.
Trilogy Writing & Consulting Limited
At Trilogy, medical writing is our passion. As specialists in clinical regulatory documentation, we provide a service that is more than just writing. We work as an outsourcing partner for our clients, and our writers are integral parts of our clients’ teams: proactively planning, coordinating, and writing their clinical and scientific communications documentation to meet aggressive timelines, with a readability that reduces the time for review and approval.
We have been helping pharmaceutical companies and clinical research organisations (CROs) of all sizes, worldwide, to streamline their documentation processes for over a decade. If you are looking for ways to save time and money in your pre- and post-marketing programmes, Trilogy can help. We cover all clinical areas and will be happy to talk to you about how to increase the speed and effectiveness of your documentation.
Clinical documentation and scientific communications are far too important to be left to chance. No programme is too small for well-written protocols, study reports or submission dossiers. The success of clinical development programmes, drug approval, and marketing depends ultimately on the readability and reviewer-friendliness of the documentation.
Barry DreesSenior Partner
XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.
It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically,XenoGesis can identify the potential 'winners' and 'losers' in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.
To read the latest XenoGesis news CLICK HERE.